Infants and children 6 months through age 4 who received the three-dose primary series of the Pfizer-BioNTech COVID-19 vaccine are now eligible for a fourth dose — Pfizer’s bivalent booster shot.
The U.S. Food and Drug Administration (FDA) on Tuesday amended the Emergency Use Authorization (EUA) of Pfizer bivalent COVID-19 booster vaccine for the younger age group, but only for those children who received the three-dose series before the FDA authorized Pfizer’s bivalent Omicron booster as the third shot in the primary series.
Under the amended authorization, children can receive their fourth shot two months after completing the three-dose primary series.
Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research, said the authorization gave parents the opportunity to “update their children’s protection.”
But critics including Peter McCullough, M.D., MPH, an internist and cardiologist, said the shots pose long-term safety concerns for children.
“I am greatly concerned about the long-term safety of accumulating novel mRNA and Wuhan spike protein in previously healthy children,” McCullough told The Defender. “Continued shots are not natural and cannot make their bodies healthier.”
Mary Holland, president and general counsel of Children’s Health Defense said:
“If one ever needed proof of which side the FDA is on, Pharma’s or the people’s, one need look no further than its authorization of a fourth COVID shot for children under 5.
“With knowledge that these shots don’t work and that they can cause severe harm, including death, this decision is simply obscene.”…